Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dicerna Pharmaceuticals : Names Rob Ciappenelli Chief Strategy Officer

09/22/2021 | 08:06am EST


ę MT Newswires 2021
All news about DICERNA PHARMACEUTICALS, INC.
11/22INSIDER SELL : Dicerna Pharmaceuticals
MT
11/22SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Dicerna Pharm..
PR
11/22Stifel Downgrades Dicerna Pharmaceuticals to Hold From Buy, Adjusts Price Target to $38..
MT
11/22Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day..
MT
11/22NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/19B. Riley Downgrades Dicerna Pharmaceuticals to Neutral from Buy After Announcing $3.3 B..
MT
11/19RBC Downgrades Dicerna Pharmaceuticals to Sector Perform From Outperform, Lifts PT to $..
MT
11/18SHAREHOLDER ALERT : WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.
PR
11/18HC Wainwright Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts PT to $38..
MT
11/18Health Care Stocks Ending Little Changed in Quiet Trading
MT
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 193 M - -
Net income 2021 -127 M - -
Net cash 2021 544 M - -
P/E ratio 2021 -23,4x
Yield 2021 -
Capitalization 2 988 M 2 988 M -
EV / Sales 2021 12,7x
EV / Sales 2022 13,6x
Nbr of Employees 302
Free-Float 92,8%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | DRNA | US2530311081 | MarketScreener
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 38,25 $
Average target price 34,96 $
Spread / Average Target -8,59%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagßn Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.72.95%2 988
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.21.78%65 758
VERTEX PHARMACEUTICALS-13.76%51 819